Drug intelligence / Profile preview

NB21-mFc

Development stage: Unknown
Lead developer: Ruijin Hospital
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NB21-mFc is a recombinant fusion protein consisting of a monoclonal antibody fragment (NB21) fused to the Fc region of mouse IgG. Information about specific targets, mechanism of action, and indications is limited in publicly available sources, suggesting it is likely an experimental research tool or preclinical-stage therapeutic. The Fc fusion confers increased stability and half-life compared to single-chain antibodies and may enable immune effector functions via Fc-mediated activity.

Targets

LGR4 (Leucine-rich repeat-containing G-protein coupled receptor 4)

Beyond the preview

Go deeper on NB21-mFc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB21-mFc.

Explore the full profile